Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209584 · ClinicalTrials.gov registry record
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
A clinical trial of Prostate Cancer, sponsored by Myriad Genetic Laboratories.
- Completed
- Registry status
- 274
- Enrollment target
- 1
- Study location
NCT02209584: Completed study of Prostate Cancer, sponsored by Myriad Genetic Laboratories.
NCT02209584 is a study of Prostate Cancer that has completed, run by Myriad Genetic Laboratories. The registered enrollment target is 274 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02209584, a study of Prostate Cancer, has completed, sponsored by Myriad Genetic Laboratories.
- COMPLETED
- Registry status
- 274 participants
- Enrollment target
- 1
- Study location
Study Summary
This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.
Conditions Studied
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-12-08 |
What the finished NCT02209584 record still lists
NCT02209584 is an observational study that tracks outcomes without assigning an intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02209584 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT02209584 about?
NCT02209584 is a clinical study titled "Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients". This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.
What is the current status of trial NCT02209584?
This trial is currently completed. The enrollment target is 274 participants. The study started on 2014-05. Estimated completion is 2015-12-08.
What conditions does trial NCT02209584 study?
This clinical trial studies the following conditions: Prostate Cancer.
Who is sponsoring clinical trial NCT02209584?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02209584 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02209584's enrollment target sits among peer trials
274 177th of 735 higher than 558 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia